D2 receptor agonists are highly effective in controlling prolactin secretion and tumor size in prolactinomas [47,48], and beneficial actions of D2 agonists have also been reported in GH- and ACTH-secreting pituitary tumors [49,50]. This evidence concerns the gene PRL and neoplasm.